Bristol Myers Squibb (BMY)

Total Liabilities

$65.32B

Quarterly · Period ending: · USD

BMY logo

BMY Total Liabilities

Latest reported$65.32B
BMY Quarterly Total Liabilities ($2.76B → $65.32B)
High-resolution chart · PNG

BMY total liabilities history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Bristol Myers Squibb Total Liabilities — Quarterly (USD)
Period endingTotal Liabilities (USD)
65,315,000,000
66,374,000,000
71,532,000,000
78,289,000,000
77,187,000,000
74,979,000,000
76,215,000,000
76,470,000,000
77,577,000,000
82,483,000,000
65,674,000,000
62,201,000,000
61,459,000,000
62,395,000,000
65,702,000,000
65,462,000,000
67,696,000,000
71,389,000,000
73,308,000,000
73,609,000,000
73,923,000,000
74,762,000,000
80,599,000,000
75,306,000,000
78,916,000,000
79,308,000,000
78,246,000,000
39,679,000,000
39,012,000,000
19,517,000,000
20,859,000,000
19,984,000,000
20,223,000,000
20,177,000,000
21,704,000,000
19,063,000,000
18,588,000,000
18,402,000,000
17,360,000,000
17,946,000,000
17,753,000,000
17,341,000,000
17,324,000,000
16,506,000,000
16,663,000,000
17,890,000,000
18,766,000,000
18,249,000,000
18,124,000,000
17,893,000,000
23,356,000,000
22,090,000,000
21,879,000,000
22,259,000,000
22,259,000,000
22,144,000,000
15,855,000,000
16,162,000,000
17,103,000,000
15,578,000,000
15,688,000,000
14,950,000,000
15,438,000,000
15,915,000,000
15,477,000,000
15,520,000,000
16,223,000,000
16,580,000,000
15,873,000,000
16,564,000,000
17,278,000,000
15,538,000,000
17,286,000,000
15,764,000,000
15,610,000,000
14,945,000,000
16,413,000,000
15,830,000,000
15,584,000,000
15,626,000,000
15,690,000,000
15,905,000,000
16,930,000,000
14,341,000,000
14,432,000,000
18,026,000,000
20,233,000,000
19,513,000,000
18,554,000,000
17,827,000,000
17,662,000,000
16,463,000,000
16,302,000,000
16,063,000,000
16,266,000,000
15,772,000,000
14,069,000,000
14,183,000,000
18,737,000,000
14,700,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.